A new strategy for monitoring of direct oral anticoagulants in patients with cyanotic and complex congenital heart disease
2024

Monitoring Direct Oral Anticoagulants in Patients with Congenital Heart Disease

Sample size: 11 publication Evidence: low

Author Information

Author(s): Dirbach Fabienne, Goulouti Eleni, Bouchardy Judith, Ladouceur Magalie, Alberio Lorenzo, Rutz Tobias

Primary Institution: Lausanne University Hospital and University of Lausanne

Hypothesis

Can a new strategy for monitoring direct oral anticoagulants improve safety and efficacy in patients with cyanotic and complex congenital heart disease?

Conclusion

The proposed monitoring strategy for direct oral anticoagulants could enhance safety and efficacy in patients with cyanotic and complex congenital heart disease.

Supporting Evidence

  • Ten out of eleven patients had D-dimers and DOAC trough levels in the target range.
  • One patient required a switch to vitamin K antagonists due to insufficient DOAC efficacy.
  • Minor complications occurred in three patients, but no major complications were observed.

Takeaway

Doctors are trying a new way to check if blood thinners are working well for patients with heart problems, which could help keep them safe.

Methodology

This retrospective study collected clinical, imaging, and laboratory data from patients with cyanotic and complex congenital heart disease requiring oral anticoagulation.

Limitations

The study is limited by a small and heterogeneous cohort and varying follow-up durations.

Participant Demographics

Eleven adult patients (mean age 38 years, range 19–60 years) with cyanotic and complex congenital heart disease.

Digital Object Identifier (DOI)

10.1016/j.ijcchd.2024.100545

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication